researchers develop new method of regenerating bone tissue using gene therapy

Home Forums Continuing education researchers develop new method of regenerating bone tissue using gene therapy

Welcome Dear Guest

To create a new topic please register on the forums. For help contact : discussdentistry@hotmail.com

Currently, there are 0 users and 1 guest visiting this topic.
Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #10755
    Drsumitra
    Offline
    Registered On: 06/10/2011
    Topics: 238
    Replies: 542
    Has thanked: 0 times
    Been thanked: 0 times

    Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a new method of repairing bone using synthetic bone graft substitute material, which combined with gene therapy, can mi

    Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a new method of repairing bone using synthetic bone graft substitute material, which combined with gene therapy, can mimic real bone tissue and has potential to regenerate bone in patients who have lost large areas of bone from either disease or trauma.

    The researchers have developed an innovative scaffold material (made from collagen and nano-sized particles of hydroxyapatite) which acts as a platform to attract the body’s own cells and repair bone in the damaged area using gene therapy. The cells are tricked into overproducing bone producing proteins known as BMPs, encouraging regrowth of healthy bone tissue. This is the first time these in-house synthesised nanoparticles have been used in this way and the method has potential to be applied to regenerate tissues in other parts of the body.

    Professor Fergal O’Brien, Principal Investigator on the project explained: “Previously, synthetic bone grafts had proven successful in promoting new bone growth by infusing the scaffold material with bone producing proteins. These proteins are already clinically approved for bone repair in humans but concerns exist that the high doses of protein required in clinical treatments may potentially have negative side effects for the patient such as increasing the risk of cancer. Other existing gene therapies use viral methods which also carry risks”.

    “By stimulating the body to produce the bone-producing protein itself, using non-viral methods these negative side effects can be avoided and bone tissue growth is promoted efficiently and safely,” Professor O’Brien said.

    The research is the result of a collaborative project carried out between the Tissue Engineering Research Group led by Professor Fergal O’Brien and Dr. Garry Duffy in the Department of Anatomy, RCSI; Professor Kazuhisa Bessho, Kyoto University, Japan, and Dr. Glenn Dickson, Queen’s University Belfast, Northern Ireland and consists of a multi-disciplinary research effort between cell biologists, clinicians and engineers. Results of this study were recently published in the esteemed materials science journal Advanced Materials (1) with Dr. Caroline Curtin, a postdoctoral researcher in the Department of Anatomy, RCSI, as first author.

    Bone grafts are second only to blood transfusions on the list of transplanted materials worldwide with approximately 2.2 million procedures performed annually (2) at an estimated cost of $2.5 billion per year (3). At present, the majority of these procedures involve either transplanting bone from another part of the patient’s own body (autograft) or from a donor (allograft). However, these procedures have a number of risks such as infections or the bone not growing properly at the area of transplantation. Therefore there is a large potential market for bone graft substitute materials such as the innovative scaffolds being developed by the RCSI team and their collaborators.

    While the biomaterials developed in this project have undoubted potential for bone repair with the capability to act as a superior alternative to existing bone graft treatments, this gene delivery platform may also have significant potential in the regeneration of other degenerated or diseased tissues in the body when combined with different therapeutic genes. This is currently a major focus of ongoing research in the Tissue Engineering Research Group which has a particular interest in using the platform to deliver genes that promote the formation of blood vessels (using angiogenic genes) in the regeneration of tissues which suffer from compromised blood supply such as heart wall tissue which has been damaged following a heart attack.

    This research was funded by the European Research Council under the European Community’s Seventh Framework Programme and a Science Foundation Ireland, President of Ireland Young Researcher Award.

     

     

    #15915
    Drsumitra
    Offline
    Registered On: 06/10/2011
    Topics: 238
    Replies: 542
    Has thanked: 0 times
    Been thanked: 0 times

    One of the most important indications for guided tissue regeneration (GTR) treatment is class II furcation lesion. However, periodontal regeneration of this type of defect, although possible, is not considered totally predictable, especially in terms of complete bone fill. Many factors may account for variability in the response to regenerative therapy in class II furcation. The purpose of this review is to assess the prognostic significance of factors related to the patient (smoking, stress, diabetes mellitus, acquired immunodeficiency syndrome and other acute and debilitating diseases, and the presence of multiple deep periodontal pockets), local factors (furcal anatomy, defect morphology, thickness of gingival tissue and tooth mobility), surgical treatment (infection control, bone replacement grafts combined with barriers or GTR alone, type of barrier and surgical technique), and postoperative period (plaque control, membrane exposure, membrane retrieval and a regular supportive periodontal care program) for successful of GTR in class II furcations.

     

Viewing 2 posts - 1 through 2 (of 2 total)
  • You must be logged in to reply to this topic.